Successful Management of Neonatal Kaposiform Haemangioendothelioma and Kasabach-Merritt Phenomenon Using Sirolimus and Surgical Excision

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Brieflands

Abstract

Kaposiform haemangioendothelioma (KHE) is a rare vascular tumor, occurring predominantly in infancy, with an incidence of 0.091 per 100,000 children. Typically presenting as a solitary large cutaneous lesion, with no distant metastases. Children with KHE are at high-risk of developing Kasabach-Merritt Phenomenon (KMP), a consumptive coagulopathy. KMP is defined as profound thrombocytopenia, hypofibrinogenemia, and elevated D-dimer. KMP has a mortality of 10 - 30%. Due to its rarity, there is little robust evidence for KHE management. Rapamycin (mTOR) inhibitors have been shown to be a safe and effective treatment. This report is regarding a newborn term female who presented at birth with an abdominal cutaneous vascular malformation, subsequently developing life-threatening thrombocytopenia and coagulopathy. She was diagnosed with KHE complicated by KMP, with an excellent response to sirolimus treatment, with subsequent lesion resection.

Description

Keywords

Citation

URI

Endorsement

Review

Supplemented By

Referenced By